View more job listings or post a job
Abiosciences Inc. Sales Manager / Senior Sales Manager
SyntheX Research Scientist: Yeast Geneticist with Strong Molecular Biology Background
SyntheX Research Scientist: Biochemist with Strong Molecular Biology Background
SyntheX Research Scientist: Cancer Biology
Pyrotech Therapeutics, Inc. Head of Biology (Executive Director/Vice President)
Genentech Senior/Principal Scientific Researcher, DMPK LC-MS Bioanalysis
Assembly Biosciences Associate Director, DMPK
San Jose State University SJSU Master of Biotechnology  
AtomicAI ( (Senior) Scientist, RNA Biology
AtomicAI ( (Senior) Research Associate, Molecular Biology
Post a job


[Free Online Symposium] Oxbryta¬ģ (Voxelotor) tablets for Sickle Cell Disease: The R&D Journey and Lessons Learned (jointly by PBSS and CLSA)

Speakers: Mira Pochron PhD (Head of Translational Biology, Global Blood Therapeutics)
Organizers: Dennis Hu, Cyrus Khojasteh and Dewakar Sangaraju (all of Genentech)
Date: 2021-02-16
Time: 12:00-13:30 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor: (1)CLS
Vendor show vendors registered to date:
Registration deadline:2021-02-15  (it will close sooner if the seating cap is reached)

About the Topic

Building upon nearly 70 years of research in sickle cell disease (SCD) pathology, voxelotor, an HbS polymerization inhibitor, was developed to treat

the root cause of SCD pathophysiology. In 2019, the FDA granted Oxbryta® (Voxelotor) accelerated approval using hemoglobin, a biologic surrogate endpoint, indicative of reduced SCD hemolysis. In this presentation, we will share the R&D journey of Oxbryta®.

This presentation is part of the symposium series “Success Stories of Recently Approved Drugs and Lessons Learned”, jointly organized by PBSS and CLSA (California Life Science Association, a trade association representing California’s life science industry).

About the Speakers

Mira Pochron, PhD

Staff Scientist, Head of Translational Biology

Global Blood Therapeutics, Inc

Dr. Mira Pochron currently serves as the Head of Translational Biology at Global Blood Therapeutics (GBT). During her tenure at GBT she was an integral part of developing and overseeing the collection of pharmacodynamic data in the phase 1/2a studies with voxelotor and continues to oversee the collection of pharmacodynamic and biomarker data. She has been with GBT since it’s early days in 2011 and been a core team member involved in assay development, compound screening and animal studies with Hb modifiers, such as voxelotor. Dr. Pochron received her Ph.D. in Chemistry and Biochemistry from University of California, Santa Cruz.

2021-12-06, [Free Online Webcast] Regenerative Medicine: Latest Advances and Case Studies
2021-12-07, [Free Online Seminar] Fighting pancreatic cancer: current treatments, pipeline landscape, and PanCAN's drug development projects
2022-01-21, [Free Online Symposium] Food Safety and Animal Health
2022-02-01, [Free Online Seminar] My experience and observations in building a contract service business
©Pharmaceutical & BioScience Society, International; Last Modified: 12/2/2021; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Limited Synthesis, purification & NMR characterization of drug metabolites at mg-g scale with COAs, including CYP/AOX/FMO metabolites, glucuronides & sulfates
iPRECIO Programmable Pumps by Primetech Corporation Unprecedented PK-PD correlations in in-Vivo Pharmacology? Learn more on Linkedin- registration page. iPRECIO Programmable pump info at
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad